• info@reportsandmarkets.com
  • +44-020-3286-9338 (UK) +1-214-377-1121 (US)
  • Sign In
  • Register

OtherGlobal Human Immunodeficiency Virus (HIV)-1 Therapeutics Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023

  • RnM2414269
  • |
  • 14 September, 2018
  • |
  • Global
  • |
  • 120 pages
  • |
  • GIR (Global Info Research)
  • |
  • Other

The human immunodeficiency virus (HIV) is a lentivirus (a subgroup of retrovirus) that causes HIV infection and over time acquired immunodeficiency syndrome (AIDS).AIDS is a condition in humans in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive.

Scope of the Report:

This report studies the Human Immunodeficiency Virus (HIV)-1 Therapeutics market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Human Immunodeficiency Virus (HIV)-1 Therapeutics market by product type and applications/end industries.

The key factors responsible for driving the market growth include the increasing incidence of HIV infections especially amongst the youth due to unprotected sexual practices, exposure to needles or syringes contaminated with infected body fluids or tissues, lack of awareness regarding transmission risk factors, etc.

The global Human Immunodeficiency Virus (HIV)-1 Therapeutics market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.

The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.

North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Human Immunodeficiency Virus (HIV)-1 Therapeutics.

Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.

Market Segment by Companies, this report covers

AbbVie, Inc.(U.S.)

Merck & Co., Inc. (U.S.)

Bristol-Myers Squibb Company (U.S.)

Boehringer Ingelheim GmbH (Germany)

Genentech, Inc. (U.S.)

Cipla, Inc. (India)

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)

Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

Entry and Fusion Inhibitors

Protease Inhibitors (PIs)

Integrase Inhibitors

Coreceptor Antagonists

Market Segment by Applications, can be divided into

Hospitals

Clinics

Labs


Table of Contents

1 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Overview

1.1 Product Overview and Scope of Human Immunodeficiency Virus (HIV)-1 Therapeutics

1.2 Classification of Human Immunodeficiency Virus (HIV)-1 Therapeutics by Types

1.2.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Comparison by Types (2017-2023)

1.2.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share by Types in 2017

1.2.3 Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)

1.2.4 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

1.2.5 Entry and Fusion Inhibitors

1.2.6 Protease Inhibitors (PIs)

1.2.7 Integrase Inhibitors

1.2.8 Coreceptor Antagonists

1.3 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market by Application

1.3.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size and Market Share Comparison by Applications (2013-2023)

1.3.2 Hospitals

1.3.3 Clinics

1.3.4 Labs

1.4 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market by Regions

1.4.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size (Million USD) Comparison by Regions (2013-2023)

1.4.1 North America (USA, Canada and Mexico) Human Immunodeficiency Virus (HIV)-1 Therapeutics Status and Prospect (2013-2023)

1.4.2 Europe (Germany, France, UK, Russia and Italy) Human Immunodeficiency Virus (HIV)-1 Therapeutics Status and Prospect (2013-2023)

1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Human Immunodeficiency Virus (HIV)-1 Therapeutics Status and Prospect (2013-2023)

1.4.4 South America (Brazil, Argentina, Colombia) Human Immunodeficiency Virus (HIV)-1 Therapeutics Status and Prospect (2013-2023)

1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Human Immunodeficiency Virus (HIV)-1 Therapeutics Status and Prospect (2013-2023)

1.5 Global Market Size of Human Immunodeficiency Virus (HIV)-1 Therapeutics (2013-2023)

2 Manufacturers Profiles

2.1 AbbVie, Inc.(U.S.)

2.1.1 Business Overview

2.1.2 Human Immunodeficiency Virus (HIV)-1 Therapeutics Type and Applications

2.1.2.1 Product A

2.1.2.2 Product B

2.1.3 AbbVie, Inc.(U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

2.2 Merck & Co., Inc. (U.S.)

2.2.1 Business Overview

2.2.2 Human Immunodeficiency Virus (HIV)-1 Therapeutics Type and Applications

2.2.2.1 Product A

2.2.2.2 Product B

2.2.3 Merck & Co., Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

2.3 Bristol-Myers Squibb Company (U.S.)

2.3.1 Business Overview

2.3.2 Human Immunodeficiency Virus (HIV)-1 Therapeutics Type and Applications

2.3.2.1 Product A

2.3.2.2 Product B

2.3.3 Bristol-Myers Squibb Company (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

2.4 Boehringer Ingelheim GmbH (Germany)

2.4.1 Business Overview

2.4.2 Human Immunodeficiency Virus (HIV)-1 Therapeutics Type and Applications

2.4.2.1 Product A

2.4.2.2 Product B

2.4.3 Boehringer Ingelheim GmbH (Germany) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

2.5 Genentech, Inc. (U.S.)

2.5.1 Business Overview

2.5.2 Human Immunodeficiency Virus (HIV)-1 Therapeutics Type and Applications

2.5.2.1 Product A

2.5.2.2 Product B

2.5.3 Genentech, Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

2.6 Cipla, Inc. (India)

2.6.1 Business Overview

2.6.2 Human Immunodeficiency Virus (HIV)-1 Therapeutics Type and Applications

2.6.2.1 Product A

2.6.2.2 Product B

2.6.3 Cipla, Inc. (India) Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue, Gross Margin and Market Share (2016-2017)

3 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Competition, by Players

3.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue and Share by Players (2013-2018)

3.2 Market Concentration Rate

3.2.1 Top 5 Human Immunodeficiency Virus (HIV)-1 Therapeutics Players Market Share

3.2.2 Top 10 Human Immunodeficiency Virus (HIV)-1 Therapeutics Players Market Share

3.3 Market Competition Trend

4 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size by Regions

4.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue and Market Share by Regions

4.2 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue and Growth Rate (2013-2018)

4.3 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue and Growth Rate (2013-2018)

4.4 Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue and Growth Rate (2013-2018)

4.5 South America Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue and Growth Rate (2013-2018)

4.6 Middle East and Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue and Growth Rate (2013-2018)

5 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Countries

5.1 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Countries (2013-2018)

5.2 USA Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue and Growth Rate (2013-2018)

5.3 Canada Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue and Growth Rate (2013-2018)

5.4 Mexico Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue and Growth Rate (2013-2018)

6 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Countries

6.1 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Countries (2013-2018)

6.2 Germany Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue and Growth Rate (2013-2018)

6.3 UK Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue and Growth Rate (2013-2018)

6.4 France Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue and Growth Rate (2013-2018)

6.5 Russia Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue and Growth Rate (2013-2018)

6.6 Italy Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue and Growth Rate (2013-2018)

7 Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Countries

7.1 Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Countries (2013-2018)

7.2 China Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue and Growth Rate (2013-2018)

7.3 Japan Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue and Growth Rate (2013-2018)

7.4 Korea Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue and Growth Rate (2013-2018)

7.5 India Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue and Growth Rate (2013-2018)

7.6 Southeast Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue and Growth Rate (2013-2018)

8 South America Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Countries

8.1 South America Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Countries (2013-2018)

8.2 Brazil Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue and Growth Rate (2013-2018)

8.3 Argentina Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue and Growth Rate (2013-2018)

8.4 Colombia Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue and Growth Rate (2013-2018)

9 Middle East and Africa Revenue Human Immunodeficiency Virus (HIV)-1 Therapeutics by Countries

9.1 Middle East and Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue by Countries (2013-2018)

9.2 Saudi Arabia Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue and Growth Rate (2013-2018)

9.3 UAE Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue and Growth Rate (2013-2018)

9.4 Egypt Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue and Growth Rate (2013-2018)

9.5 Nigeria Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue and Growth Rate (2013-2018)

9.6 South Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue and Growth Rate (2013-2018)

10 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Segment by Type

10.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue and Market Share by Type (2013-2018)

10.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecast by Type (2018-2023)

10.3 Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs) Revenue Growth Rate (2013-2023)

10.4 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Revenue Growth Rate (2013-2023)

10.5 Entry and Fusion Inhibitors Revenue Growth Rate (2013-2023)

10.6 Protease Inhibitors (PIs) Revenue Growth Rate (2013-2023)

10.7 Integrase Inhibitors Revenue Growth Rate (2013-2023)

10.8 Coreceptor Antagonists Revenue Growth Rate (2013-2023)

11 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Segment by Application

11.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Share by Application (2013-2018)

11.2 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecast by Application (2018-2023)

11.3 Hospitals Revenue Growth (2013-2018)

11.4 Clinics Revenue Growth (2013-2018)

11.5 Labs Revenue Growth (2013-2018)

12 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Forecast (2018-2023)

12.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Forecast (2018-2023)

12.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecast by Regions (2018-2023)

12.3 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Forecast (2018-2023)

12.4 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Forecast (2018-2023)

12.5 Asia-Pacific Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Forecast (2018-2023)

12.6 South America Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Forecast (2018-2023)

12.7 Middle East and Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Market Forecast (2018-2023)

13 Research Findings and Conclusion

14 Appendix

14.1 Methodology

14.2 Data Source


captcha
Enter the code in the box:


captcha
Enter the code in the box:

Single User License (PDF)

  • This license allows for use of a publication by one person.
  • This person may not print out a single copy of the publication.
  • This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
  • This person cannot share the publication (or any information contained therein) with any other person or persons.
  • Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
  • Customers who infringe these license terms are liable for a Global license fee.

 

Site License (PDF)*

  • This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
  • These users may print out a single copy of the publication.
  • These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
  • These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
  • Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
  • Customers who infringe these license terms are liable for a Global license fee.

 

Global License (PDF)*

  • This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
  • Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
  • These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.


captcha
Enter the code in the box:



Summary:
Get latest Market Research Reports on Human Immunodeficiency Virus (HIV)-1 Therapeutics . Industry analysis & Market Report on Human Immunodeficiency Virus (HIV)-1 Therapeutics is a syndicated market report, published as Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023. It is complete Research Study and Industry Analysis of Human Immunodeficiency Virus (HIV)-1 Therapeutics market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.


REPORT YOU MIGHT BE INTERESTED

Purchase this Report

$3,480.00
$5,220.00
$6,960.00
2,336.82
3,505.23
4,673.64
3,202.30
4,803.44
6,404.59
421,567.20
632,350.80
843,134.40
230,770.63
346,155.95
461,541.26
Add To Cart Credit card Logo

Related Reports


Reason to Buy